The project is a basic research work that facilitates the development of drugs in the long term that can prevent the spread of metastases. The research will run over four years and contribute to strengthening the long-term cooperation between Norway and France. The project has been created simultaneously with a newly established framework agreement for cancer research between Norway, the Institut Curie and other French institutions. Former Director of Radiumhospitalet and current Director at Radiumhospitalets Legater, Jan Vincent Johannessen, has been instrumental for the success of the research agreement.
The discovery of protrudin as a key protein in invadopodia (among the effectuators of cancer metastases) by Camilla Raiborg and the Stenmark team was a crucial contribution to the foundation of the collaboration and was published in Nature in 2015.